文章：

嵌合抗原受体T细胞疗法治疗胶质母细胞瘤

Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma

原文发布日期：30 November 2023

DOI: 10.3390/cancers15235652

类型: Article

开放获取: 是

英文摘要：

Glioblastoma (GBM), the most common primary brain tumor in adults, is characterized by low survival rates and a grim prognosis. Current treatment modalities, including extensive surgical resection, chemotherapy, and radiation therapy, often yield limited success due to the brain’s sensitivity, leading to significant side effects. Exciting advancements in immunotherapy have recently shown promise in treating various types of tumors, raising hopes for improved outcomes in brain tumor patients. One promising immunotherapy approach is chimeric antigen receptor (CAR) T-cell therapy, which recognizes surface proteins on targeted tumor cells and redirects cytotoxicity towards specific targets. This review aims to discuss the existing research and future prospects for CAR T-cell immunotherapy in treating glioblastoma.

摘要翻译： 

胶质母细胞瘤（GBM）是成人中最常见的原发性脑肿瘤，其特点是生存率低且预后不良。目前的治疗方式，包括广泛手术切除、化疗和放射治疗，由于大脑的敏感性，往往效果有限，并导致显著的副作用。近年来，免疫疗法的激动进展已在多种肿瘤治疗中显示出潜力，为脑肿瘤患者带来了改善预后的希望。嵌合抗原受体（CAR）T细胞疗法作为一种有前景的免疫治疗策略，能够识别靶向肿瘤细胞表面的蛋白质，并将细胞毒性重定向至特定目标。本综述旨在探讨CAR T细胞免疫疗法在治疗胶质母细胞瘤方面的现有研究及未来前景。

原文链接：

Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma